title: Effect of adolescent exposure to WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference.
abstract: The present study employs a conditioned place preference procedure (CPP) to examine the effects of exposure to the cannabinoid agonist WIN 55212-2 (WIN) (0.1 and 0.5mg/kg) during adolescence on the reinforcing properties of +/-3,4-methylenedioxymetamphetamine hydrochloride (MDMA) (1.25 and 2.5mg/kg) in mice. On postnatal day (PD) 27, animals received a daily injection of the assigned treatment on 5 consecutive days, and three days later the place conditioning procedure was initiated (PD 35). The results suggest that pre-exposure to cannabinoids strengthens the properties of MDMA and favors reinstatement of the craving for the drug, which endorses the gateway hypothesis.
authors.affiliation: Facultad de Psicología, Departamento de Psicobiología, Unidad de Investigación Psicobiología de las Drogodependencias, Universitat de Valencia, Avda. Blasco Ibáñez 21, 46010 Valencia, Spain.
authors.forename: Marta
authors.initials: M
authors.lastname: Rodríguez-Arias
authors.forename: Carmen
authors.initials: C
authors.lastname: Manzanedo
authors.forename: Concepción
authors.initials: C
authors.lastname: Roger-Sánchez
authors.forename: Bruno Ribeiro
authors.initials: BR
authors.lastname: Do Couto
authors.forename: María Asunción
authors.initials: MA
authors.lastname: Aguilar
authors.forename: José
authors.initials: J
authors.lastname: Miñarro
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D048588:Benzoxazines / Q000008:administration & dosage*; D002121:Calcium Channel Blockers / Q000008:administration & dosage*; D063387:Cannabinoid Receptor Antagonists; D003216:Conditioning, Operant / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005108:Extinction, Psychological / Q000187:drug effects; D006213:Hallucinogens / Q000494:pharmacology; D008297:Male; D051379:Mice; D009025:Morpholines / Q000008:administration & dosage*; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000494:pharmacology; D009281:Naphthalenes / Q000008:administration & dosage*; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D012055:Reinforcement Schedule; D000077285:Rimonabant; D013037:Spatial Behavior / Q000187:drug effects*; D013997:Time Factors
chemical_list: D048588:Benzoxazines; D002121:Calcium Channel Blockers; D063387:Cannabinoid Receptor Antagonists; D006213:Hallucinogens; D009025:Morpholines; D009281:Naphthalenes; D010880:Piperidines; D011720:Pyrazoles; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D000077285:Rimonabant